

AMICUS AND NORGINE SIGN DISTRIBUTION CONTRACT FOR MOVIPREP® IN MACEDONIA AND SERBIA

PRESS RELEASE NO. 19

Amicus SA of Baar, Switzerland and Norgine BV of Amsterdam, the Netherlands signed a long-term distribution agreement under which Amicus will register and launch MOVIPREP®, one of Norgine's bowel preparations, in Macedonia and Serbia.

Baar, Switzerland, November 28th, 2017: Amicus S.A. announced today that it had signed a long-term distribution agreement with Norgine B.V. of Amsterdam, the Netherlands. Under the agreement, Amicus will be responsible to register, obtain pricing and reimbursement, and then promote and medically support the launch of MOVIPREP® (Macrogol 3350) in both Macedonia and Serbia. Norgine developed and launched MOVIPREP® in 2005.

MOVIPREP® is a market leading bowel preparation in Europe," commented Predrag Lukic, GM of Amicus Serbia and Regional Director for Albania, Bosnia, Kosovo, Macedonia and Montenegro. "We are delighted to collaborate with Norgine and we are excited to launch MOVIPREP®. It offers a great combination of efficacy and safety at an affordable price. Indeed, MOVIPREP® is already included in many East European countries' clinical guidelines, and we hope to achieve similar access for patients in Macedonia and Serbia. MOVIPREP® is a two litre bowel preparation, offering a choice of flavours; which provides a better alternative than the current four litre bowel preparation standard of care."

"We look forward to launch MOVIPREP® in Macedonia and Serbia," Lukic continued, "and to work with both the Serbian medical community and our government to improve bowel cancer detection rates in Serbia, and thereby to improve patients' lives."

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine's total revenue was EUR 368 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.

NORGINE, the sail logo and MOVIPREP are trademarks of the Norgine group of companies.

For more information about Norgine, please visit <http://www.norgine.com/>

About Amicus S.A.

Amicus subsidiaries operate in the Balkan and Baltic countries of Croatia, Estonia, Kosovo, Latvia, Lithuania, Macedonia, Montenegro, Serbia and Slovenia. The company commenced operations with a new Hungarian affiliate in July, 2017 and is currently opening affiliates in Albania and Bulgaria. Set up in 2014, Amicus has gathered outstanding pharmaceutical, Medical Device and OTC / consumer

healthcare talent. The company specializes in representing research-based pharmaceutical, medical equipment and self-care brands across the Central and Eastern Europe.

For more info about Amicus, please visit: www.amicuspharma.eu

Contact:

Maja Boskovic, Public Affairs Officer, Amicus

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321